Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Syner-G: Miglustat and Ketogenic Diet for Gangliosidoses
NCT02030015Phase 4Terminated
- Sponsor
- University of Minnesota
- Start
- Dec 2015
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of miglustat in GM1 gangliosidosis (GM1) and GM2 gangliosidosis, sponsored by University of Minnesota. Primary endpoint: Duration of Survival at 60 months. Started Dec 2015; status: terminated.
02
Drugs
miglustat
03
Conditions
GM1 gangliosidosis (GM1)GM2 gangliosidosis
Beyond the preview
Go deeper on NCT02030015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030015.